Moomoo AIのまとめ
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
2024年1月19日、アルタミラ・セラピューティクスは、H.C. Wainwright ＆ Co.、LLCとのAt the Market Offering Agreementを発表し、最大166万ドル相当の普通株式を販売する予定です。販売は、市場価格である現行の市場価格でNasdaq Capital Marketまたは他の取引プラットフォームを通じて行われます。H.C. Wainwright＆Co.は、売却株式の総売価に対する3.0％の手数料を受け取ります。オファリングには最低販売要件がなく、販売株式数とアルタミラ・セラピューティクスへの純収入はまだ決定されていません。売上合計が166万ドルに...すべて展開
2024年1月19日、アルタミラ・セラピューティクスは、H.C. Wainwright ＆ Co.、LLCとのAt the Market Offering Agreementを発表し、最大166万ドル相当の普通株式を販売する予定です。販売は、市場価格である現行の市場価格でNasdaq Capital Marketまたは他の取引プラットフォームを通じて行われます。H.C. Wainwright＆Co.は、売却株式の総売価に対する3.0％の手数料を受け取ります。オファリングには最低販売要件がなく、販売株式数とアルタミラ・セラピューティクスへの純収入はまだ決定されていません。売上合計が166万ドルに達するか、いずれかの当事者が契約を終了するまで、オファリングは続きます。これは、同社が2023年12月にA.G.P./Alliance Global Partnersとの以前のat-the-marketオファリングプログラムを終了した後のもので、約1306万ドル相当の普通株式が売却されました。
役に立った
役に立たない